News NICE close to clearing Cancer Drugs Fund backlog Only five drugs left to assess from old scheme.
News NICE recommends Celgene pancreatic cancer drug Abraxane finally gets NHS funding following price cut.
News Roche's Tecentriq hits trouble with NICE in bladder cancer Cancer Drugs Fund could cover costs in first line use.
News Teva's Cinqaero to challenge Nucala after clearing NICE Discount swings NICE decision, drug will compete with GSK rival
News Disappointment as government delays pharma-friendly policies Proposals fall short of ambitions of Accelerated Access Review.
News Alexion price cut opens up Strensiq to more patients Managed access scheme will control costs to NHS.
News FDA clears first all-oral combo for first-line CLL treatment AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
